Vicapsys Life Sciences, Inc.
VICP
$1.77
$0.5039.37%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 195.10K | 171.80K | 203.90K | 527.20K | 172.20K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 198.90K | 181.80K | 204.30K | 527.20K | 175.40K |
| Operating Income | -198.90K | -181.80K | -204.30K | -527.20K | -175.40K |
| Income Before Tax | -235.50K | -190.10K | -327.10K | -594.80K | -240.30K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -235.50K | -190.10K | -327.10K | -594.80K | -240.30K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -235.50K | -190.10K | -327.10K | -594.80K | -240.30K |
| EBIT | -198.90K | -181.80K | -204.30K | -527.20K | -175.40K |
| EBITDA | -- | -- | -- | -519.40K | -167.60K |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.02 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.02 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
| Average Basic Shares Outstanding | 34.33M | 34.19M | 32.07M | 34.98M | 34.41M |
| Average Diluted Shares Outstanding | 34.33M | 34.19M | 32.07M | 34.98M | 34.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |